Immune therapy with macrophages: Present status and critical requirements for implementation

Immunobiology

Volumn 195, Issue 4-5, 1996, Pages 550-562

  Bartoleyns, Jacques ^a,b   Romet Lemonne, Jean Loup ^b   Chokri, Mohamed ^b   Lopez, Manuel ^c  

^a LFB   (France)

^b Immuno Designed Molecules   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; CANCER IMMUNOTHERAPY; CELL DIFFERENTIATION; CELL TRANSFER; CONFERENCE PAPER; CONTROLLED STUDY; EXPERIMENTAL NEOPLASM; GENE THERAPY; HUMAN; HUMAN CELL; MACROPHAGE; MACROPHAGE ACTIVATION; METHODOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0029833190     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0171-2985(96)80021-0     Document Type: Conference Paper

References (50)

1. ROSENBERG, S., M. LOTZE, L. MUUL, A. CHANG, and F. AVIS. 1990a. Progress report on the treatment of 157 patients with advanced cancer using LAK cells and IL2 or IL2 alone. N. Engl. J. Med. 316: 889.
2. ROSENBERG, S., B. PACKARD, P. AEBERSOLD, D. SOLOMON, and S. TOPALIAN. 1990b. Use of tumor infiltrating lymphocytes and IL2 in the immunotherapy of patients with metastatic melanoma. N. Engl. J. Med. 319: 1676.
3. STEVENSON, H. C. 1989. Adoptive cellular immunotherapy of cancer, 242 pp, M. Dekker inc. N.Y. Basel.
4. BARTHOLEYNS, J., M. LOPEZ, and R. ANDREESEN. 1991. Adoptive immunotherapy of solid tumors with activated macrophages: experimental and clinical results. Anticancer Res. 11: 1201.
5. REES, R., and H. PARRY. 1992. Macrophages in tumor immunity. In: The Macrophage, MC GEE & LEWIS (ed.). IRL Press, Oxford, pp 315.
6. FOGLER, W., and I. FIDLER. 1988. Therapeutic circumvention of the biologic heterogeneity in malignant neoplasms by tumoricidal macrophages. In: Macrophages and cancer, HEPPNER & FULTON (ed.). CRC Press, pp 147.
7. FIDLER, I. 1985. Macrophages and metastases. A biological approach to cancer therapy. Cancer Res. 45: 4714.
8. DULLENS, H., F. KINGMA, and W. DEN OTTER. 1974. Eur. J. Cancer 10: 41.
9. FIDLER, I., J. JESSUP, W. OJOFLER, R. STAERKEL, and A. MAZUMBER. 1986. Activation of tumoricidal properties in peripheral blood monocytes of patients with colorectal carcinoma. Cancer Res. 46: 994.
10. BARTHOLEYNS, J., Y. LOMBARD, S. DUMONT, D. HARTMANN, M. CHOKRI, J. GIAIMIS, S. FAUFMANN, and P. POINDRON. 1988. Immunotherapy of cancer: experimental approach with activated macrophages proliferating in culture. Cancer Detect. & Prev. 12: 413.
11. CHOKRI, M., M. FREUDENBERG, C. GALANOS, P. POINDRON, and J. BARTHOLEYNS. 1989. Antitumoral effect of LPS, TNF, IFN, and activated macrophages: synergism and tissue distribution. Anticancer Res. 9: 1185.
12. DUMONT, S., D. HARTMANN, P. POINDRON, A. FARADJI, F. OBERLING, and J. BARTHOLEYNS. 1988. Control of the antitumoral activity of human macrophages produced in large amount in view of adoptive transfer. Eur. J. Cancer 24: 1691.
13. CHAKRABORTY, N., T. OKINO, and P. STABACH. 1991. Adoptive transfer of activated human autologous macrophages results in regression of human melanoma cells in Scid mice. In Vivo 5: 609.
14. ANDREESEN, R., C. SCHEIBENBOGEN, W. BRUGGER, S. KRAUSE, H. MEERPHOHL, H. LESER, and G. LOHR. 1990. Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating monocytes: a new approach to cancer immunotherapy. Cancer Res. 50: 7450.
15. FARADJI, A., A. BOHBOT, M. SCHMITT, N. ROESLIN, S. DUMONT, M. WIESEL, C. LALLOT, M. EBER, J. BARTHOLEYNS, P. POINDRON, G. MORAND, J. WITZ, and F. OBERLING. 1991. Phase 1 trial of IV infusion of ex-vivo activated blood derived macrophages in patients with non small cell lung cancer: toxicity and immunomodulatory effects. Cancer Immunol. Immunother. 33: 319.
16. LOPEZ, M., J. FECHTENBAUM, B. DAVID, C. MARTINAGHE, M. CHOKRI, S. CANEPA, A. DE GRAMONT, C. LOUVET, I. GORIN, O. MORTEL, and J. BARTHOLEYNS. 1992. One step separation by elutriation of monocytes from leukapheresis products of cancer patients for production of IFNg activated macrophages in view of adoptive immunotherapy. J. Immunotherapy 11: 209.
17. FARADJI, A., A. BOHBOT, M. SCHMITT, J. C. SIFFERT, S. DUMONT, M. WIESEL, Y. PIEMONT, A. EISCHEN, J. P. BERGERAT, J. BARTHOLEYNS, P. POINDRON, J. P. WITZ, and F. OBERLING. 1994. Large scale isolation of human blood monocytes by continuous flow centrifugation elutriation for adoptive cellular immunotherapy in cancer patients. J. Immmunol. Methods 174: 297.
18. ANDREESEN, R., W. BRUGGER, C. SCHEIBENBOGEN, M. KREUTZ, H. LESER, A. RHEM, and G. LOHR. 1990a. Surface phenotype analysis of human monocytes to macrophages differentiation. J. Leuk. Biol. 47: 490.
19. STERCK, R., E. HURLEY, D. EPSTEIN, and J. PAULY. 1992. Tumour cytolytic human monocyte-derived macrophages: a simple and efficient method for the generation and long term cultivation as non adherent cells in a serum free medium. Res. Immunol. 143: 79.
20. TAIMI, M., H. DEFACQUE, T. COMMES, J. FAVERO, E. CARON, J. MARTI, and J. DORMAND. 1993. Effect of retinoic acid and vitamin D on the expression of interleukin 1, tumor necrosis factor and interleukin 6 in the human monocytic line U937. Immunol. 79: 229.
21. KRIST, L., M. KERREMANS, and H. KOENEN. 1995. Novel isolation and purification method permitting functional cytotoxicity studies of macrophages from milky spots in the greater omentum. J. Immunol. Meth. 184: 253.
22. PARDOLL, D. 1995. Paracrine cytokine adjuvants in cancer immunotherapy. Ann. Rev. Immunol. 13: 399.
23. CHONG, Y., G. HEPPNER, L. PAUL, and A. FULTON. 1989. Macrophage mediated induction of DNA strand breaks in target tumor cells. Cancer Res. 49: 6652.
24. AUDRAN, R., L. DAZORD, and L. TOUJAS. 1994. Interaction between human macrophages and tumor cells in three dimensional cultures. Canc. Immunol. Immunother. 39: 299.
25. NATHAN, C., L. BRUKNER, G. KAPLAN, J. UNKELESS, and Z. COHN. 1980. Role of activated macrophages in antibody dependent cell lysis of tumor cells. J. Exp. Med. 152: 97.
26. MUNN, D., and N. CEUNG. 1989. Antibody dependent antitumor cytotoxicity by human monocytes cultures with rMCSF. J. Exp. Med. 170: 511.
27. SAVIL, J., V. FADOK, P. HENSON, and C. HASLETT. 1993. Phagocyte recognition of cells undergoing apoptosis. Immunol. Today 14: 131.
28. PECK, R., M. BROCKHAUS, and J. FREY. 1989. Cell surface TNF accounts for monocyte and lymphocyte killing of TNF resistant target cells. Cell Immunol. 122: 1.
29. ODA, S., M. SATO, S. TOYOSHIMA, and T. OSAWA. 1989. binding of activated macrophages to tumor cells through a macrophage lecton and its role in macrophage tuoricidal activity. J. Biochem. 105: 1040.
30. CHU, E., L. CASEY, J. HARRIS, and D. BRAUN. 1993. Suppression of the development of tumoricidal function in gamma interferon treated peripheral blood monocytes by LPS: the role of cyclooxygenase metabolites. J. Clin. Immunol. 13: 49.
31. YAMAMOTO, N., J. ZOU, and H. TAKENADA. 1995. Regulatory mechanisms for production of IFN and TNF by T cells or macrophages in the tumor bearing state. J. Immunol. 154: 2281.
32. AOE, T., Y. OKAMOTO, and T. SAITO. 1995. Activated macrophages induce structural abnormalities of the T cell receptor-CD3 complex. J. Exp. Med. 181: 1881.
33. MUNN, D., A. BEAL, D. SONG, R. WRENN, and D. THROCKMORTON. 1995. Activation induced apoptosis in human macrophages. J. Exp. Med. 181: 127.
34. MACKAY, R., PACE, M. JARPE, and S. RUSSELL. 1989. Macrophage activation associated proteins. Characterization of stimuli and conditions needed for expression of proteins. J. Immmunol. 142: 1639.
35. ARMSTRONG, D., W. OGIER, and J. MALUTA. 1995. Clinical systems for the production of human cells and tissues. Biotechnology 13: 449.
36. ANDERSON, C. 1992. Gene therapy researcher under fire over controversial cancer trials. Nature 360: 399.
37. TRAVERSARI, C., P. VAN DER BRUGGEN, I. LUESCHER, and T. BOON. 1992. A nonapeptide encoded by human gene Magel is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2E. J. Exp. Med. 176: 1453.
38. American 82.
39. ZEMBALA, M., and G. ASHERSON. 1989. Human monocytes. Academic Press, London San Diego, pp 353.
40. UNAHUE, E. 1984. Antigen presenting function of the macrophage. Ann. Rev. Immunol. 2: 395.
41. BETJES, M., C. TUK, D. STRUYK, R. KREDIET, L. ARISZ, and R. BEELEN. 1993. Ag presenting capacity of macrophages and dendritic cells in the peritoneal cavity of patients treated with peritoneal dialysis. Clin. Exp. Immunol. 94: 377.
42. EVANS, R. 1986. The immunological network at the site of tumor rejections. Biochim. Biophys. Acta 865: 1.
43. HADDADA, H., M. LOPEZ, C. MARTINACHE, T. RAGOT, M. ABINA, and M. PERRICAUDET. 1993. Efficient adenovirus mediated gene transfer into human blood monocyte-derived macrophages. Biochem. Biophys. Res. Comm. 195: 1174.
44. DAGSLEISH, A. 1994. Cancer Vaccines. Eur. J. Cancer 30: 1029.
45. DOHERTY, M. 1995. T cell regulation of macrophage function. Current opinion in immunol. 7: 400.
46. CHELEN, C., Y. FANG, G. FREEMEN, H. SECRIST, J. MARSHALL, P. HWANG, L. FRANKEL, R. DEKRUYF, and D. UMETSU. 1995. Human alveolar macrophages present antigen ineffectively due to defective expression of B7 costimulatory cell surface molecules. J. Clin. Invest. 95: 1415.
47. DRANOFF, G., and R. MULLIGAN. 1995. Gene transfer as cancer therapy. Advances in Immunol. 58: 417.
48. CHOKRI, M., A. GIRARD, M. BORRELLY, C. OLERON, J. ROMET-LEMONNE, and J. BARTHOLEYNS. 1992. Adoptive immunotherapy with bispecific antibodies: targeting through macrophages. Res. Immunol. 143: 95.
49. ADAMS, D., and T. HAMILTON. 1988. Activation of macrophages for tumor cell kill: effector mechanisms and regulation. In: Macrophages and cancer, HEPPNER & FULTON (eds.). CRC Press F1; pp 27-38.
50. ARCECI, R. 1995. Mechanisms of resistance to therapy and tumor cell survival. Current Op in Hematol. 2: 268.